Expert Interview
Follow-up Discussing how payers are strategizing pricing and reimbursement for cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Ticker(s): VRTX, BLUE, CRSPExperienced, motivated candidate with a strong background in the Healthcare Finance industry; supplemented with an MBA degree. Held various positions as senior financial analyst in most of the leading Healthcare providers and Insurance companies. Managing team by motivating, exciting, and keeping team members focused. Excellent project management and time management skills, in both agile and traditional project management. Served as an expert Business Leader in implementing code editing software ClaimsXten, Change HealthCare, Covid19 Reimbursement, Expert in HealthCare Reimbursement Commercial and Medicaid, Federal Regulatory Alignment - Pricing Transparency- No Surprise Act . Ability to provide exceptional and accurate analysis, by translating complex financial data into simple strategic imperatives for decision making.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
